TY - JOUR
T1 - Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin
T2 - Results from the SYNERGY trial
AU - Lopes, Renato D.
AU - Alexander, Karen P.
AU - Marcucci, Gretchen
AU - White, Harvey D.
AU - Spinler, Sarah
AU - Col, Jacques
AU - Aylward, Philip E.
AU - Califf, Robert M.
AU - Mahaffey, Kenneth W.
N1 - Funding Information:
Conflict of interest: R.D.L., K.P.A. and G.M. had no conflict to declare. H.D.W., J.C., P.E.A., R.M.C., and K.W.M. were supported by research grants from sanofi-aventis. S.S. received honoraria from sanofi-aventis.
PY - 2008/8
Y1 - 2008/8
N2 - Aims: Elderly patients are at high risk from non-ST-segment elevation acute coronary syndromes (NSTE ACS) as well as from treatment-related complications. Age-associated changes in physiology may alter the risk and benefit expected from therapy. The SYNERGY database was used to study the influence of age on treatment outcomes with enoxaparin vs. unfractionated heparin (UFH) in patients with high-risk NSTE ACS. Methods and results: Age was analysed as a continuous and categorical variable (<65, 65-74, and ≥75 years, and <75 and ≥75 years) for descriptive purposes. Logistic regression was used to adjust the outcomes of 30-day death, death or myocardial infarction (MI), and major bleeding for baseline characteristics. Odds ratios compared outcomes by age and by treatment within age groups. Model interaction terms were used to test for statistically different outcomes by treatment and age. Overall, 9977 randomized patients had age information, of whom 25.5% (2540) were ≥75 years of age. Elderly patients (≥75 years) had more cardiovascular risk factors, prior cardiac disease, and higher acuity at presentation. After adjustment, advanced age (per 10 years) was associated with 30-day death or MI [risk odds ratios (ROR): 1.14, P = 0.002], 30-day death (ROR: 1.54, P < 0.0001), and 1-year death (ROR: 1.47, P < 0.0001), as well with TIMI major bleeding (ROR: 1.21, P = 0.001), GUSTO severe bleeding (ROR: 1.20, P = 0.047), and transfusion (ROR: 1.04, P = 0.324). Although there was a higher rate of GUSTO severe bleeding noted with enoxaparin in elderly patients, the overall relationships between treatment (UFH or enoxaparin) and outcomes did not vary significantly as a function of the patient's age. Conclusion: Although higher rates of adverse events are seen in the oldest subgroup (age ≥75 years) treated with enoxaparin, statistical comparisons confirm similar efficacy and safety of enoxaparin and UFH across age subgroups as was demonstrated overall in SYNERGY.
AB - Aims: Elderly patients are at high risk from non-ST-segment elevation acute coronary syndromes (NSTE ACS) as well as from treatment-related complications. Age-associated changes in physiology may alter the risk and benefit expected from therapy. The SYNERGY database was used to study the influence of age on treatment outcomes with enoxaparin vs. unfractionated heparin (UFH) in patients with high-risk NSTE ACS. Methods and results: Age was analysed as a continuous and categorical variable (<65, 65-74, and ≥75 years, and <75 and ≥75 years) for descriptive purposes. Logistic regression was used to adjust the outcomes of 30-day death, death or myocardial infarction (MI), and major bleeding for baseline characteristics. Odds ratios compared outcomes by age and by treatment within age groups. Model interaction terms were used to test for statistically different outcomes by treatment and age. Overall, 9977 randomized patients had age information, of whom 25.5% (2540) were ≥75 years of age. Elderly patients (≥75 years) had more cardiovascular risk factors, prior cardiac disease, and higher acuity at presentation. After adjustment, advanced age (per 10 years) was associated with 30-day death or MI [risk odds ratios (ROR): 1.14, P = 0.002], 30-day death (ROR: 1.54, P < 0.0001), and 1-year death (ROR: 1.47, P < 0.0001), as well with TIMI major bleeding (ROR: 1.21, P = 0.001), GUSTO severe bleeding (ROR: 1.20, P = 0.047), and transfusion (ROR: 1.04, P = 0.324). Although there was a higher rate of GUSTO severe bleeding noted with enoxaparin in elderly patients, the overall relationships between treatment (UFH or enoxaparin) and outcomes did not vary significantly as a function of the patient's age. Conclusion: Although higher rates of adverse events are seen in the oldest subgroup (age ≥75 years) treated with enoxaparin, statistical comparisons confirm similar efficacy and safety of enoxaparin and UFH across age subgroups as was demonstrated overall in SYNERGY.
KW - Age
KW - Enoxaparin
KW - Non-ST-segment elevation acute coronary syndromes
KW - Outcomes
KW - Unfractionated heparin
UR - http://www.scopus.com/inward/record.url?scp=48749122759&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehn236
DO - 10.1093/eurheartj/ehn236
M3 - Article
C2 - 18519426
AN - SCOPUS:48749122759
SN - 0195-668X
VL - 29
SP - 1827
EP - 1833
JO - European heart journal
JF - European heart journal
IS - 15
ER -